Sharecare (SHCR)
(Real Time Quote from BATS)
$1.38 USD
0.00 (0.00%)
Updated Aug 8, 2024 01:44 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SHCR 1.38 0.00(0.00%)
Will SHCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SHCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SHCR
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates
SHCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Sharecare, Inc. (SHCR) to Report a Decline in Earnings: What to Look Out for
Sharecare, Inc. (SHCR) Reports Q4 Loss, Lags Revenue Estimates
GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates
Other News for SHCR
SHCR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Sharecare to Boston Scientific
Key Takeaways From Sharecare Analyst Ratings
Sharecare price target raised by 43c at Morgan Stanley, here's why
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)
Hold Rating on Sharecare Amid Private Acquisition and Market Challenges